Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of tirzepatide in adults with overweight or obesity to reduce cardiovascular events, diabetes onset, and kidney outcomes
CTR20223054Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Jan 2023; status: active.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20223054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223054.